This study is for newborns exposed to HIV-1, a virus that affects the immune system. Researchers want to see how safe and effective a medication called Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) is for these babies. They're also studying how the medicine moves through the body, which is called pharmacokinetics (PK). Babies in this study should be born at full-term (after 37 weeks of pregnancy), weigh at least 2.5 kg (about 5.5 pounds), and be able to take medicine by mouth. Mothers need to be on a standard HIV treatment and not breastfeeding if they are on a B/F/TAF regimen. Babies cannot join if they have certain medical conditions or if they've already been exposed to parts of the study medication.

• Must be born at full-term and weigh at least 2.5 kg.
• Study checks how the medicine is absorbed and works in the body.
• Mothers should not breastfeed while on certain medications.